Camlin Fine Sciences Q4FY26 Results: Net Loss of ₹564.95 Lakh
Camlin Fine Sciences reported a standalone net loss of ₹564.95 lakh for Q4FY26. Total income from operations was ₹18,351.65 lakh. Consolidated net profit was ₹8,627.73 lakh with total income of ₹1,72,330.81 lakh for the year.
The financial results, particularly the standalone net loss, are material to investors. However, the consolidated results show a profit for the year, mitigating some of the negative impact.
The company reported a net loss on a standalone basis for the quarter, which is a negative financial outcome.
Camlin Fine Sciences Limited has announced its audited financial results for the quarter and year ended March 31, 2026. For the quarter, the company reported a total income from operations of ₹18,351.65 lakh on a standalone basis and ₹42,481.12 lakh on a consolidated basis.
On a standalone basis, the net profit (loss) after tax from continuing operations was a loss of ₹564.95 lakh. The total comprehensive income for the period was a loss of ₹664.17 lakh. Earnings per share (EPS) on a basic and diluted basis were ₹(0.29).
Consolidated figures show a total income from operations of ₹1,72,330.81 lakh for the year ended March 31, 2026. The net profit (loss) after tax and non-controlling interests was ₹8,627.73 lakh. The total comprehensive income for the period was ₹7,438.53 lakh. Basic and diluted EPS were ₹4.59 and ₹4.54, respectively.
The company has stated that the above information is an extract of the detailed format of audited results filed with the stock exchanges and that the full format is available on the company's website and the stock exchange websites.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.